Breaking News
0

The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams And Verisk

By Zacks Investment ResearchStock MarketsJun 11, 2019 09:52PM ET
www.investing.com/analysis/the-zacks-analyst-blog-highlights-intel-altria-stryker-sherwinwilliams-and-verisk-200430887
The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams And Verisk
By Zacks Investment Research   |  Jun 11, 2019 09:52PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

For Immediate Release

Chicago, IL –June 12, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel (NASDAQ:INTC) , Altria (NYSE:MO) , Stryker (NYSE:SYK) , Sherwin-Williams (NYSE:SHW) and Verisk (NASDAQ:VRSK) .

Here are highlights from Tuesday’s Analyst Blog:

Top Stock Reports for Intel, Altria and Stryker

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Intel, Altria and Stryker. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Intel’s shares have outperformed the Zacks General Semiconductor industry in the past year, losing -14.7% vs. a decline of -21.1%. The Zacks analyst thinks Intel is benefiting from rising demand for its higher performance products, both in data center and client domains. Strength in Xeon ASPs is a key catalyst.

Moreover, synergies from Mobileye (F:0ME) acquisition and growing clout in ADAS market favor Intel’s growth prospects. Intel's strategy of expanding TAM beyond CPU to adjacent product lines like silicon photonics, fabric, network ASICs, and 3D XPoint memory is yielding results.

However, declining trend in PC shipments is detrimental to business prospects of Intel, which continues to depend substantially on PC sales. Also, weakness in demand from China and softness in NAND flash pricing trends, remain major concerns. Intensifying competition and pricing pressure from AMD remains a headwind.

(You can read the full research report on Intel here >>>).

Shares of Altria have lost -8.1% over the past three months, outperforming the Zacks Tobacco industry, which has declined -9.3% over the same period. The Zacks analyst stresses that the company is grappling with declining cigarette shipment volumes.

Stern FDA regulations, along with increased health consciousness are taking a toll on cigarette sales. During first-quarter 2019, domestic cigarette shipment volumes fell 14.3% year over year. Going forward, management expects cigarette industry volume to decline by 4-5%. Nevertheless, growing popularity of Smokeless products offers some respite. During the first quarter, revenues in the category improved nearly 2.9%.

To further bolster this unit, the company has made investments in JUUL and Cronos. Pricing also continues to drive the company’s revenues. It has also undertaken cost-reduction initiatives and plans to deliver annualized cost savings of nearly $575 million by the end of 2019.

(You can read the full research report on Altria here >>>).

Stryker’s shares have gained +20.7% in the past year, outperforming the Zacks Medical Products industry, which has increased +4.8% over the same period. The Zacks analyst thinks the company continues to gain from its core MedSurg unit which put up a strong show in the reported quarter.

Additionally, strength in flagship Mako platform continues to favor the company. Moreover, its K2M acquisition drove the core Neurotechnology & Spine unit in the quarter under review. Solid international growth also buoys optimism. Expansion in operating margins is a positive while strong outlook for 2019 is indicative of bright prospects.

Stryker exited the first quarter of 2019 on a solid note, with earnings surpassing the consensus mark and revenues increasing on a year-over-year basis. However, contraction in gross margin is a concern. Pricing pressure also continues to plague Stryker. Stiff competition in the MedTech space remains a headwind.

(You can read the full research report on Stryker here >>>).

Other noteworthy reports we are featuring today include Sherwin-Williams and Verisk.

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

Click to get it free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.



Verisk Analytics, Inc. (VRSK): Free Stock Analysis Report

Stryker Corporation (SYK): Free Stock Analysis Report

The Sherwin-Williams Company (SHW): Free Stock Analysis Report

Altria Group, Inc. (MO): Free Stock Analysis Report

Intel Corporation (INTC): Free Stock Analysis Report

Original post

Zacks Investment Research
The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams And Verisk
 

Related Articles

The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams And Verisk

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email